Real-World Comparison of Cardiorenal Outcomes With SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists in Type 2 Diabetes

Diabetes, obesity & metabolism · 2026 Nov 2 · Huang CH, Wu JL, Ling TC et

By Maren Holt · Senior Reporter, GLP-1

Nov 1 19:00 ETSource: Diabetes, obesity & metabolism

From the source

Real-World Comparison of Cardiorenal Outcomes With SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists in Type 2 Diabetes
Diabetes, obesity & metabolism · 2026 Nov 2 · Huang CH, Wu JL, Ling TC et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42972883/